May 8, 2025 | Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient management. Listen to previous episodes Receive the the ...

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.

With both new and revised measures, the document’s authors aim to provide clinicians usable advice in a digestible format.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...

Cath labs need to be redesigned so that operators aren’t at risk for future injury, even if it requires some hospital ...

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

Not surprisingly, older patients fared worse, but some older and younger patients saw stroke benefits requiring more study.

A trend toward higher mortality in women with PPM who received a self-expanding valves deserves more scrutiny, though.

Though women have a lower risk of ventricular arrhythmias than do men, it still exceeds the threshold to justify a device.